PharmaShots | Incisive News in 3 Shots

Subscribe Now

Relapsed or Refractory Multiple Myeloma

$BeiGene's Kyprolis (carfilzomib) Receives NMPA's Conditional Approval for the Treatment of Relapsed or Refractory Multiple Myeloma$

BeiGene's Kyprolis (carfilzomib) Receives NMPA's Conditional Approval for the Treatment of Relapsed or Refractory Multiple Myeloma

July 9, 2021

$AbbVie Acquire TeneoOne and its TNB-383B for the Treatment of Relapsed or Refractory Multiple Myeloma$

AbbVie Acquire TeneoOne and its TNB-383B for the Treatment of Relapsed or Refractory Multiple Myeloma

June 25, 2021

$Janssen and SpringWorks Reports Dosing of First Patient in P-Ib trial for Nirogacestat + Teclistamab to Treat Relapsed or Refractory Multiple Myeloma$

Janssen and SpringWorks Reports Dosing of First Patient in P-Ib trial for Nirogacestat + Teclistamab to Treat Relapsed or Refracto...

April 2, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us